RNA Studies Resolve An Uncertain Variant In MYBPC3 In A Large Pedigree
HFSA 2026
Rachel Keppers, Laura Ongie, Erica D. Smith, Heather Zimmerman, Sarah Kreykes, Lauren Boucher
Introduction
Pathogenic variants in MYBPC3 are associated with a spectrum of cardiomyopathies, including hypertrophic cardiomyopathy (HCM) and left ventricular noncompaction cardiomyopathy (LVNC) that are inherited in autosomal dominant or recessive patterns. Due to the known genetic and phenotypic heterogeneity of cardiomyopathies, it can be difficult to establish pathogenicity for a given variant. Multiple lines of evidence are often required to correctly interpret a variant. We present a case that demonstrates how RNA testing can complement more traditional lines of evidence such as segregation to clarify variant interpretation and provide families with impactful cardiac risk information.
Case Presentation
The proband was diagnosed with hypertrophic cardiomyopathy at age 28 with a clinical phenotype strongly suggestive of sarcomeric disease. Informative relatives across multiple generations included 12 individuals with HCM plus three who died from sudden cardiac death. Genetic testing of the proband in 2019 identified intronic MYBPC3 c.2149-9C>G, at the time classified as a variant of uncertain significance (VUS). The MYBPC3 VUS was identified in 3 additional affected relatives in follow up testing. An additional VUS in gene DSP, c.2644G>A (p.E882K), was identified in two out of three affected relatives tested. We ruled out the variant in DSP as the primary diagnosis due to failure to segregate with disease, but we cannot eliminate the possibility that it may contribute to disease presentation or severity in carriers.
RNA studies, Follow Up
RNA analysis confirmed retention of 8 intronic nucleotides from the variant allele, resulting in a frameshift and premature truncation. This event was seen at a 52% PSI in the proband’s affected first cousin once removed and at 56% in another similarly affected relative with the variant, while it was not seen in any of the 3 controls. Addition of this information was sufficient to reclassify MYBPC3 c.2149-9C>G to likely pathogenic. After the MYBPC3 variant was reclassified as likely pathogenic, six healthy family members pursued proactive genetic testing. Four were found to carry the MYBPC3 variant, and they plan to proceed with regular screening echocardiograms. All family members expressed gratitude and relief for genetic testing that can determine their risk.
Discussion
Multiple factors contributed to the successful clinical outcome. The family was highly motivated and informed: the proband’s aunt was a strong historian who provided detailed family health information and previous genetic testing results. Other family members were also eager and willing to participate in research testing, and only six months passed between the initial appointment and reclassification of the variant. The type of variant identified also affected the outcome. As this was an intronic variant, RNA analysis was able to help resolve the VUS interpretation. Other functional assays may be required to resolve other types of variants. The use of RNA analysis has become increasingly common in other genetic testing specialties such as oncology. This case demonstrates that RNA analysis can also inform VUS resolution in cardiomyopathy genes.
Related publications